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Combination versus sequential single agent chemotherapy in advanced
breast cancer: associations with metastatic sites and long-term survival
R.T. Chlebowski, R.V. Smalley, J.M. Weiner, L.E. Irwin, A.A. Bartolucci & J.R. Bateman
The Western Cancer Study Group and the Southeastern Cancer Study Group
Summary Two hundred and twenty-two patients with advanced breast cancer were randomised in two
separate trials of similar design to either concomitant combination treatment or sequential use of the same
drugs given as single agents changed only at disease progression. Both trials used cyclophosphamide,
methotrexate, 5-fluorouracil and prednisone; the WCSG using triiodothyronine and the SECSG using
vincristine as the remaining agent. A common data base was generated for these trials and combined for
analysis. Considering all patients, combination treatment was associated with a significantly increased
response (46 versus 25%, P<0.05) but not survival improvement. For the 141 patients without liver
involvement, survival was closely comparable in both treatment arms. Combination therapy did result in
significant survival benefit for patients with liver involvement (P<0.05). These studies demonstrate: (1) in the
majority of breast cancer patients, sequential single agent therapy can result in survival comparable to
combination treatment; and (2) sole consideration of response frequency does not represent the optimal
criterion to compare therapeutic approaches in advanced breast cancer.
Metastatic adenocarcinoma of the breast has been treated
with combination chemotherapy for over 20 years
(Greenspan et al., 1963; Cooper, 1969). During this period,
many trials have reported higher response frequencies for
combination chemotherapy compared to those achieved with
single agent treatment (Henderson, 1987; Kieser & Conrad,
1987). Consequently, combination chemotherapy has become
a standard approach for patients with metastatic breast
cancer receiving chemotherapy (DeVita et al., 1975). How-
ever, when parameters such as prolongation of survival and/
or effective palliation of symptoms are used as criteria for
effectiveness, greater difficulty in identifying a 'standard
therapy' for metastatic breast cancer has become apparent
(Hayes & Henderson, 1987). To this end, several recent
breast cancer trial reports have emphasised long-term survi-
val results in populations receiving therapeutic regimens with
different intensity (Aisner et al., 1987; Lopinzi & Ahmann,
1986; Taylor et al., 1986).
In an attempt to define whether populations of advanced
breast cancer patients can be successfully treated with regi-
mens involving less intensive therapy, two large cooperative
oncology groups, the Western Cancer Study Group (WCSG)
and the Southeastern Cancer Study Group (SECSG)
initiated similar chemotherapy trials for patients with meta-
static breast cancer. These cooperative groups randomised
patients between five drug combination chemotherapy and
sequential use of single agent chemotherapy with the treat-
ment agent changed when disease progression occurred. In
both cooperative groups, higher response frequencies were
observed on the combination treatment arm, and these trials
were initially interpreted as supporting the superiority of
combination over sequential therapy in advanced breast
cancer (Smalley et al., 1976; Chlebowski et al., 1981). The
long-term information on survival and response for sub-
groups of patients in these trials is the subject of the current
report.
Materials and methods
Between 1971 and 1973 the WCSG and SECSG entered
patients on separate protocols comparing combination
chemotherapy with five drugs to the sequential use of the
same drugs given as single agents. Patient eligibility factors
were similar in both studies and included: (1) histologically
confirmed adenocarcinoma of the breast with metastases; (2)
measurable disease parameters; and (3) no prior cytotoxic
chemotherapy. Patients who either had failed hormonal
therapy or had rapidly progressive disease were eligible for
the WCSG study. In SECSG study, premenopausal patients
were eligible only if they had prior ovarian oblation.
Pretreatment studies in both trials included: CBC, liver
function tests, chest X-ray, liver scan and bone survey.
Patients were also required to be less than 70 years of age,
have an ECOG performance status 3 or greater, have a
normal WBC (greater than 4,000 1 -3), normal platelet count
(greater or equal to 100,000 pl-3) and normal hepatic func-
tion. After determination of eligibility, patients were ran-
domly assigned to treatment arms using established
procedures in their respective central statistical offices.
Identical response criteria were used in both trials. Res-
ponses were classified as: complete, complete disappearance
of all measurable lesions with the appearance of no new
lesions for a period greater than or equal to one month;
partial, reduction of 50% of the cross-sectional area of all
measurable lesions with the appearance of no new lesions for
a period of greater or equal to one month; no change, minor
change, or progression of any measurable lesion during
therapy was considered as no response.
For this report, a common 48-item data base was
abstracted from both SECSG and WCSG data sets and
analysed at the WCSG Statistical Center. Curves represen-
ting survival were generated using the Kaplan-Meier method
(Kaplan & Meier, 1958). Comparisons of survival between
groups of patients was made with the Cox, Peto-Mantel test
(Peto et al., 1977). Patients categorised as having liver
involvement were those in whom liver scan abnormalities
consistent with metastatic disease were identified.
Both groups used the agents cyclophosphamide, metho-
trexate, 5-fluorouracil (5-FU) and prednisone in their trials.
The WCSG used triiodothyronine and SECSG used vincris-
tine as a fifth agent in the combination. Triiodothyronine
was used in the WCSG trial since this agent has been
reported to increase the response frequency in breast cancer
patients treated with steroid (Lemon, 1957). Patients in the
concurrent combination arms, referred to as combination,
received all five agents during their initial course of therapy.
The patients in the single agent sequential arms received the
same drugs used in the combination arms, but given indi-
vidually in sequence. Therapy with the initial single agent
(5-FU in both trials) was continued until disease progression
occurred, at which time the second single agent was begun.
The details of the drug schedules used in both trials are
outlined in Table I. The SECSG study used two schedules
for their combination treatment. Chemotherapy given to
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Table I Schedule of chemotherapy
WCSG SECSG
Sequential single agent 5-FU 15mgkg-1
week-' i.v. until relapse;
then
CTX 2mgkg-1day-1
p.o. until relapse; then
PRED 0.5mgkg-1day-
p.o. and
THY 0.005mgday-1
p.o. until relapse then
MTX 30mgm-2 week -
i.v.
5-FU 600mgm-2 week-' i.v. until relapse; then
MTX 20mgm-2 biweekly p.o. until relapse; then
CTX lOOmgm-2day-1 p.o. until relapse; then
VCR 1mgm-2 week-1 i.v. until relapse; then
PRED 45mgday-1 for 14 day, 30mgday-1 for 14
days and l5mgday-1 for 30 days p.o.
Concurrent combination MTX 30mgm-2
biweekly i.v. beginning
day 8
5-FU 15mgkg-1
biweekly i.v. beginning
day 1
THY 0.005mgday-
P.O.
CTX 2mgkg-'day-1
P.O.
PRED 0.5mgkg-1day-1
P.O.
MTX 3Omgm-2day-1 1, 8 p.o.; q28 days
5-FU 400mgm-2day-f 1, 8 i.v.; q28 days
VCR lmgm-2day-1 1, 8 i.v.; q28 days
CTX 400mgm-2day-1 1, i.v.; q28 days
PRED 80mgday-1 1-7; q28 days
MTX 20mgm-2 week-1 p.o.
5-FU 400mgm-2 week-1 i.v.
VCR lmgm-2 week-1 i.v.
CTX 100mgday- p.o.
PRED 45mgday-1 for 14
days, 30mgday-1 for 14 days
p.o. and 15mgday-1 for 28
days
patients after removal from study was similar in both arms
of the WCSG trial with comparable numbers of patients in
each arm receiving doxorubicin.
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One hundred and twenty-six patients were randomised on
the WCSG study with 121 of these evaluable for toxicity and
response. One hundred and eleven patients were randomised
in the SECSG trial with 101 evaluable for toxicity and
reponse. The reasons for exclusion included concurrent hor-
monal therapy (six cases), gross protocol violations during
early treatment (seven cases) and prior cytotoxic therapy
(two cases). The survival curves (Figures 1 and 2) illustrate
results from evaluable patients. Survival analyses were con-
ducted including all entered patients with no change in any
of the presented results. The patients receiving combination
or single agent sequential treatment were comparable in both
group trials in regard to age, disease-free interval and sites of
metastatic involvement (Table II).
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100
_ 75
g
cn
e 50
c)
0)
25
0
25
0
100
.2
2
G) 4-
C.)
0)
75
50
25
0
100 All patients
* Combination (129)
O Sequential (93)
n.s. 75
50
25
0
* Combination (49)
O Sequential (31)
P<0.05
-o -O _
f
0 1 2 3 4 5 6 7
Years
0 1 2 3 4
Years
Figure 1 Life-table analysis of survival for a
with combination as compared to those rece
sequential chemotherapy in the WCSG and S
groups. n.s. indicates no significant difference
5 6 7 *Figure 2 Life-table analysis of survival for patient subgroups
treated with combination compared to those receiving single
agent sequential therapy in the WCSG or SECSG cooperative
all patients treated groups. (a) Results in patients without liver metastasis (64% of
eiving single agent all patients); (b) results in patients without liver or lung meta-
,ECSG cooperative stasis (30% of all patients); (c) results in patients with liver
metastasis (36% of all patients).
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Table II Pretreatment characteristics of patient groups
Sites of metastases Performance
score Age Free interval
Lung Liver CNS Bone (median) (median) (<I year) % Premenopausal
Comb. (WCSG) 49% 49% 11% 57% 74 56 44% 32%
Seq. (WCSG) 48% 37% 10% 64% 68 54 41% 26%
Comb. (SECSG) 40% 28% 9% 56% 73 55 32% 40%
Seq. (SECSG) 61% 28% 3% 52% 70 55 44% 22%
initiation of chemotherapy. The survival of all patients in the
WCSG and SECSG trials is illustrated in Figure 1. As seen,
there is no difference in survival for patients receiving
combination as compared to sequential, single agent chemo-
therapy. Sixty-four per cent of patients in these trials were
free of liver involvement as determined by a normal liver-
spleen scan when treatment was begun. For this large subset
of patients without liver metastases, survival on the sequen-
tial regimen was similar at all time periods to that seen with
combination treatment (Figure 2). Thirty per cent of patients
were free of both liver and lung involvement when treatment
was begun. Only 6% of this group died within 8 months of
entry regardless of treatment received. Survival for these
patients without liver and lung metastasis was greater at all
time periods with the sequential, single agent approach to
therapy (median survival 18.4 months for single agent versus
14.3 months for combination chemotherapy, not significant).
Thirty-six per cent of patients had evidence of liver metasta-
sis when therapy was begun. For this group of patients with
liver involvement, significant benefit (Figure 2) was asso-
ciated with combination compared to single agent sequential
treatment with prolongation of survival seen (median survi-
val 10.1 months versus 5.3 months, respectively, P<0.05).
In both the WCSG and SECSG trials, objective responses
and complete responses were seen more than twice as often
in patients receiving the concurrent combination schedule
(Table III). Duration of response was also significantly
greater for the combination schedule in both the WCSG
(median 13.4 months versus 7.7 months, P<0.01) and
SECSG (median 9.2 months versus 5.1 months, P<0.05).
Patients demonstrating at least a partial objective response
lived longer than non-responding patients on both combi-
nation and sequential treatment (P<0.001) in both WCSG
and SECSG trials.
Toxic effects of treatment are given in Table IV. Haemato-
logical toxicity was more common in patients from the
WCSG trial. In both group trials, granulocytopaenia and
thrombocytopaenia were somewhat more severe in patients
receiving combination treatment. Deaths identified as being
Table III Response frequency
Total objective Complete
response response
Comb. (WCSG) 56% 15%
Seq. (WCSG) 26% 3%
Comb. (SECSG) 38% 12%
Seq. (SECSG) 18% 6%
Table IV Toxic effects of treatment regimens
Treatment regimen
Combination Sequential
WCSG SECSG WCSG SECSG
Granulocytopaenia
< 1,500 37% 32% 19% 0%
<750 11% 16% 3% 0%
Thrombopaenia
<100,000 11% 16% 8% 9%
<50,000 8% 6% 3% 6%
Treatment-
related deaths 3% 9% 0% 6%
treatment-related occurred more commonly in patients on
the combination arm (treatment related deaths occurring in
6% of combination versus 2% of sequential patients). A
similar degree of gastrointestinal toxicity was noted with
both approaches.
Discussion
In the present report, results from two separate chemo-
therapy trials were combined. These trials of the WCSG and
SECSG were initiated at the same time and involved similar
patient eligibility, treatment programmes and response
characteristics. In addition, survival patterns in all examined
subgroups were comparable in both trials. The similarity of
study design, size and patient prognostic characteristics, and
the relative homogeneity of results achieved in the WCSG
and SECSG studies meet published criteria (Elashoff, 1978)
for direct pooling of clinical trial results. Obviously, such
criteria are much more stringent than those routinely
employed in 'meta-analysis', which involves statistical com-
parison of outcomes from separate randomised trials (Sacks
et al., 1987; Dersimonian & Laird, 1986). If such stringent
criteria can be met, the direct pooling of study populations
provides a means of obtaining additional information from
completed breast cancer trials.
Based on the increased response frequency and duration of
response observed in both the WCSG and SECSG trials,
these studies have been interpreted as supporting the super-
iority of combination chemotherapy over sequential, single
agent treatment in breast cancer (Smalley et al., 1976;
Chlebowski et al., 1981). This conclusion is certainly valid
for breast cancer patients with liver involvement, who lived
significantly longer when given initial combination chemo-
therapy. However, for the majority of patients with
advanced breast cancer (those free of liver metastases),
survival was at least as long on sequential treatment as on
the combination regimen. The results from these trials
suggest that ongoing combination chemotherapy may not be
beneficial for all breast cancer patients.
In the current study, chemotherapy-related deaths were
recognised three times more frequently with combination
chemotherapy. Thus, the long-term survival of initially res-
ponding patients with disease in less threatening sites could
have been adversely affected by unrecognised toxicity result-
ing from ongoing combination chemotherapy. Recently,
increased thrombotic events were associated with combi-
nation chemotherapy in an adjuvant breast cancer therapy
experience (Levin et al., 1988). Recognition of other chemo-
therapy-related adverse effects may be more difficult in the
advanced disease setting where patient symptoms are com-
monly associated with breast cancer progression.
Single agent chemotherapy has been compared to 13
combination chemotherapy regimens in randomised trials of
patients with advanced breast cancer (Ahman et al., 1974,
1987; Baker et al., 1974; Canellos et al., 1976; Chlebowski et
al., 1979; Hoogstraten et al., 1976; Lemkin & Dollinger,
1973; Mouridsen et al., 1976; Nemoto et al., 1978; Rubens et
al., 1975; Smalley et al., 1976). Despite the fact that combi-
nation chemotherapy resulted in significantly higher objective
response frequency and complete response frequency in six
of these trials with duration of response significantly higher
in seven of these trials, no increase in overall survival was
associated with combination compared to single agent
chemotherapy in any trial. In one trial comparing CMF to230 R.T. CHLEBOWSKI et al.
melphalan, survival following the first year was greater for
combination treatment, but overall survival benefit was seen
in that study only in patients with liver metastases (Canellos
et al., 1976).
One prior study has compared sequential single agent
chemotherapy beginning with 5-FU to the same agents given
in concurrent combination (Baker et al., 1974). In that trial,
objective response frequency was somewhat higher for the
sequential single agent regimen (53% versus 43%, not signi-
ficant) and median survival was comparable (10.2 months
for sequential versus 8.6 months for combination, not signifi-
cant). One prior study compared 5-FU alone to four-drug
combination chemotherapy and also reported similar res-
ponse frequency on both arms (Lemkin & Dollinger, 1973).
Three trials have compared doxorubicin alone to combi-
nation chemotherapy, but in no study has a significant
overall survival difference emerged (Ahmann et al., 1974;
Hoogstraten et al., 1976; Nemoto et al., 1978). Thus, the
published literature is in complete agreement with the con-
clusions generated by our current analysis. This information
raises the testable hypothesis that less toxic treatment regi-
mens may result in enhanced quality of life without detrac-
ting from overall survival for the majority of patients with
advanced breast cancer.
The identification of a breast cancer patient population at
low risk of early death regardless of initial treatment sug-
gests that such patients could responsibly be given first line
investigational treatment rather than 'standard' combination
chemotherapy or hormonal therapy. This approach would
facilitate evaluation of new approaches to advanced breast
cancer management. In fact, the Cancer and Leukemia
Group B (CALGB) has recently proposed use of first line
investigational treatment for patients with advanced breast
cancer (Hayes & Henderson, 1987). Consideration of pre-
treatment patient prognostic characteristics may facilitate the
wider use of this approach in an easily defensible study
design.
It is clear from these trials that combination chemotherapy
is beneficial to breast cancer patients with liver involvement.
These prospective results are in close agreement with conclu-
sions retrospectively generated in a breast cancer population
with liver metastases treated with single agent chemotherapy
or combination chemotherapy at M.D. Anderson Hospital.
In that report, median survival was 14 months for the group
receiving combination chemotherapy compared to only five
months for the patients receiving single agent chemotherapy
(Zinser et al., 1987).
In summary, sequential single agent chemotherapy results
in survival comparable to combination chemotherapy for the
majority of patients with metastatic breast cancer (those free
of liver involvement). These data support the emerging
interest in the use of overall survival and measures of disease
palliation to compare effectiveness of different therapeutic
approaches to advanced breast cancer management.
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